eugenmed roadmap for including sex and gender in biomedical
TRANSCRIPT
![Page 1: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/1.jpg)
Hildrun Sundseth President
European Institute of Women’s Health
EUGenMed Roadmap for Including Sex & Gender in
Biomedical & Public Health Research
![Page 2: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/2.jpg)
EUGenMed Partners
• Coordinator: Charité-University Medicine Berlin Institute for Gender in Medicine (GIM) • European Institute of Women‘s Health • Maastricht University
• 2 year project, starting Oct 2013
www.eugenmed.eu
![Page 3: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/3.jpg)
EUGenMed Project
• The project will develop a Roadmap for implementing sex and gender aspects into biomedical and health research
• It will build on existing activities to develop an interdisciplinary, inclusive European Gender Health Network.
• Major activities: • Kick-off conference; workshops; roadmap conference • Generating material for different target audiences • Identification of future priorities and recommendations
![Page 4: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/4.jpg)
EUGenMed Roadmap Workshops
• WS 1: Sex and Gender in clinical research and clinical pharmacology (Charité)
• WS 2: Sex and Gender in public health and prevention, focus on risk factors for non-communicable diseases (Maastricht University)
• WS 3: Sex differences in basic biomedical research (Charité)
• WS 4: Sex and Gender in medicines regulation Sex and Gender in medical education (EIWH)
![Page 5: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/5.jpg)
Sex & Gender: IoM Definition
• Sex: Used as a classification, generally as male or female, according to the reproductive organs and functions that derive from chromosomal complement XY vs. XX
• Gender: Used to refer to a person’s self-representation as male or female, or how that person is responded to by social institutions on the basis of the individual’s gender presentation Masculine vs. feminine
![Page 6: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/6.jpg)
The Interaction Between Sex and Gender
Biological Dimension • The biological/ sex
differences between females and males are relevant for the diagnosis, treatment and progression of various diseases and medical conditions.
Social Dimension • Important social
consequences which affect health include education, employment and family life.
• Socio-economic, educational cultural, ethnicity differences can impact on patterns of behaviour and access to resources.
Often Sex and Gender interact - epigenetics
![Page 7: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/7.jpg)
Facts • Women live longer than men • The incidence and prevalence of diseases differ between men and women
• Women have higher rates of osteoporosis, auto-immune diseases, eating disorder, Alzheimers, etc
• Men have higher rates of Parkinsons, chronic liver disease, violence-related injuries, lung cancer, etc
• Some diseases affect men and women differently: CVD, lung cancer, diabetes, depression, etc
![Page 8: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/8.jpg)
Autoimmune Disease: Women and Men
• Higher prevalence in women • Research frequently neglects sex & gender differences
RA Sjögren SLE SSc MS AS0.0
2.5
5.0
7.5
10.0 FrauenMänner
Ratio
F/M
Women Men
RA: rheumatoid arthritis, SLE: lupus erythematodes, SSc: Scleroderma; MS: multple sclerosis, AS: spondylitis ankylosans
![Page 9: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/9.jpg)
Mental Illness: Men & Women
• Men: • Antisocial personality • Substance abuse • Completed suicide
• Women:
• Anxiety, depression • Eating disorders
• Attempted suicide
![Page 10: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/10.jpg)
Prevalence of CVD by Gender and Age
CDC/NCHS and NHLBI 2008
11.2
22.9
86.4
36.2
52.9
68.577.8
6.2
17.6
36.6
56.5
75.0
0102030405060708090
100
20-34 35-44 45-54 55-64 65-74 75+
Ages
Per
cen
t o
f P
op
ula
tio
n
MalesFemales
![Page 11: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/11.jpg)
Medicines Regulation Why consider S&G
• Both Sex and Gender matter in health
• Including Sex and Gender in biomedical research is good science and an important quality and safety issue
• In a just society, biomedical research must provide optimal treatment for both men and women
![Page 12: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/12.jpg)
Medicines Regulation Why consider S&G
• Medicines are safer and more effective for all when clinical research includes diverse population groups of all ages
• Women are under-represented in many clinical trials and if included, robust analysis is often lacking
• Sex differences of tissues and cells, every cell has a sex
• Women metabilise medicines differently example: Ambien - FDA halved dose for women
![Page 13: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/13.jpg)
Health Canada
“The general assumption prevailed that women did not differ from men except where their
reproductive organs were concerned and data obtained from clinical research involving men
could simply be extrapolated to women.”
Considerations for Inclusion of Women in Clinical Trials and Analysis of Data by Sex – 2013 Guidance Document
![Page 14: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/14.jpg)
Sex and Gender in Medicines Regulation
• 62 randomised clinical trials • 380 891 participants • 127 716 women
![Page 15: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/15.jpg)
Percentage (%) of Women in CVD Clinical Trials
Eur Heart J 2010; 31:1677-1685
![Page 16: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/16.jpg)
CVD – Clinical Trials with Analysis by Gender %
![Page 17: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/17.jpg)
Sex and Gender in Medicines Regulation
• Translating the evidence from S&G research into regulatory practice will lead to more targeted, effective opportunities for prevention, diagnosis, treatment and care.
![Page 18: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/18.jpg)
WS Medicines Regulation Recommendations
• Ethics Committees to develop guidelines that address inclusion of women in CTs, following good practice example from Medical University of Vienna
• Stakeholders to propose IMI project to develop robust methodology for subgroup analysis, address existing barriers for the recruitment and retention of women and older people in CTs
![Page 19: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/19.jpg)
WS Medicines Regulation Recommendations
• In preparation of implementing new Clinical Trials Regulation, EMA together with key stakeholders draft Guidelines on S&G analysis in CTs (example: Health Canada)
• Improve rigorous sex and age-specific pharmacovigilance reporting for existing products
• Address knowledge gap: develop regulatory framework for safe use of medicines during pregnancy: post-marketing data collection, common rules for pregnancy exposure registries, etc.
![Page 20: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/20.jpg)
WS Medicines Regulation Recommendations
• EMA to make sex- and age-specific data more readily available and transparent
Example: FDA Snapshot on heart failure drug: Corlanor
Source: FDA, 2015
![Page 21: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/21.jpg)
Example: FDA Snapshot Heart Failure drug: Corlanor
Source: FDA, 2015
![Page 22: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/22.jpg)
Thank you. Any questions?
European Institute of Women’s Health 33 Pearse Street, Dublin 2, Ireland
http://eurohealth.ie +353-1-671-5691 (phone)
![Page 23: EUGenMed roadmap for including sex and gender in biomedical](https://reader033.vdocuments.net/reader033/viewer/2022051711/5868c40f1a28abd1568bafc0/html5/thumbnails/23.jpg)
This project the European Gender Medicine Network (EUGenMed) has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under
grant agreement No. 602050